Several studies have used direct ADC values to predict IDH mutation or MGMT promoter methylation status of gliomas, and the area under the curve (AUC) varied from 0.686 to 0.870 (Xing et al., 2017, 2019, 2022; Cindil et al., 2022). This evidence concerns the gene IDH2 and central nervous system cancer.